Teva plunges as outlook cut for third time
Company cuts profit forecast a day after new chief executive takes over
Teva betting on Schultz as CEO with $40m package
Dane lands top job with beleaguered generics giant after reviving Lundbeck’s fortunes
Cancer drug setback knocks 15% off AstraZeneca shares
Results from long-awaited Mystic lung cancer study fail to show hoped-for patient recovery
Teva completes acquisition of Allergan’s generics business
Pharmaceutical acquisition was announced a year ago with $40.5bn price tag
Allergan shares shed 21% on plans to curb tax inversions
Pharma group agreed to merge with Pfizer last year to take advantage of Ireland’s lower corporate tax rate
Mylan admits that bid for Dublin-based Perrigo has failed
Drugmaker said it fell short of 50% share threshold in tender offer
Teva Pharmaceutical closes in on Allergan’s generics unit
Israeli drugmaker nearing deal to acquire unit for between $40 billion and $45 billion
Perrigo swiftly rejects $34.1bn raised offer from generics group Mylan
Three-way battle sees Irish group Perrigo cast as defensive foil as Mylan looks to avoid the clutches of world’s largest generics group Teva
YOU MAY ALSO LIKE...
Crosswords & Puzzles
Crosswords & puzzles to keep you challenged and entertained
Stardust
Inquests into the nightclub fire that led to the deaths of 48 people
Common Ground
How does a post-Brexit world shape the identity and relationship of these islands
Family NoticesOpens in new window
Weddings, Births, Deaths and other family notices